The purpose of the study is to evaluate the safety and effectiveness of a combination of treatments. The experimental treatment includes the drug asciminib, which is taken by mouth, alongside chemotherapy, a type of treatment using strong medicines to kill cancer cells. Following this, the drug blinatumomab, which is given through an IV infusion, may be used. Other medications that may be part of the background care include vincristine sulfate, dexamethasone, cytarabine, methotrexate, hydrocortisone, and prednisolone acetate.

The study is divided into different stages to find the most appropriate dose of the medicine. In the first stage, researchers look at how the body reacts to different amounts of the drug to ensure safety. In the second stage, the focus shifts to determining how many patients achieve complete remission, a state where all signs of cancer have disappeared. Throughout the process, doctors will monitor for any side effects or changes in health to ensure the treatment is managed carefully.

The treatment being tested in this study is called tisagenlecleucel, also known by its code name FCTX-CL19-1 or Tarcidomgen Kimleucel. This is a type of therapy known as CAR T-cell therapy, which involves modifying a patient’s own immune cells to better recognize and attack cancer cells. The purpose of the study is to evaluate the safety and effectiveness of this treatment in managing B-ALL.

Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants over a period of time to observe how well the treatment works and to identify any side effects. The goal is to determine if this therapy can help achieve remission, which means the cancer is no longer detectable, and to understand how long the benefits of the treatment last. The study will also track the overall health and survival of participants following the treatment.

The purpose of the study is to test the safety and feasibility of using CLIC-1901 CAR T-cell therapy in patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor the effects of the treatment over a period of time to understand how well it works and to identify any side effects. The trial will also look at how the treatment affects the overall health and survival of the participants.

Throughout the study, researchers will keep track of various health indicators, such as the response of the cancer to the treatment, any side effects experienced, and the overall survival of the participants. The study aims to provide valuable information on the potential benefits and risks of using CAR T-cell therapy in treating these types of blood cancers. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of the study is to see how well Blinatumomab works when added to the usual treatment plan for B-ALL. This includes using it during the early phase of treatment and again during a phase called consolidation therapy, which helps to strengthen the initial treatment’s effects. The study aims to find out how many patients achieve a state where no minimal residual disease (MRD) is detected after the first phase of consolidation therapy. MRD refers to the small number of cancer cells that might remain in the body after treatment, which can be a sign of how well the treatment is working.

Participants in the study will receive Blinatumomab as part of their treatment plan, and some may receive a placebo. The study will monitor various outcomes, such as the level of MRD after different treatment phases, the response of blood cells to the treatment, and the overall survival of patients. The study will also look at the side effects of the treatment and how the immune cells in the body respond to it. The trial is expected to continue until the end of 2025.